Winrevair (sotatercept-csrk) is used to help increase exercise capacity, improve WHO functional class, and reduce the risk of disease progression in pulmonary arterial hypertension (PAH). It functions as an activin signaling inhibitor, which helps alleviate symptoms and potentially slow disease progression.

Administration Show Full Answer

Winrevair (sotatercept-csrk) is used to help increase exercise capacity, improve WHO functional class, and reduce the risk of disease progression in pulmonary arterial hypertension (PAH). It functions as an activin signaling inhibitor, which helps alleviate symptoms and potentially slow disease progression.

Administration:
- Administered via subcutaneous injection.
- Typically, one injection every three weeks after initial treatment.
- Dose adjustments may be based on blood hemoglobin and platelet counts.
- Blood levels should be checked before each dose for the first five doses and periodically thereafter.

Common Side Effects:
- Headaches
- Nosebleeds
- Rash
- Small dilated blood vessels near the skin’s surface
- Diarrhea
- Dizziness
- Skin redness and discoloration

Serious Side Effects:
- Severe thrombocytopenia (low platelet count), increasing the risk of bleeding
- Erythrocytosis (high red blood cell count), which may lead to blood clots and hyperviscosity syndrome (thickened blood)

Precautions:
- Regular monitoring for severe side effects is necessary.
- May cause fetal harm, so contraception is advised if there's a possibility of becoming pregnant.

For more detailed experiences, you might want to connect with others on platforms like myPHteam.

 This AI-generated response comes from myPHteam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Winrevair (Sotatercept-csrk) for Pulmonary Hypertension | myPHteam

Treatments and PH | myPHteam